Zeybel, Mujdat
Altay, Ozlem
Arif, Muhammad https://orcid.org/0000-0003-2261-0881
Li, Xiangyu
Yang, Hong
Fredolini, Claudia
Akyildiz, Murat
Saglam, Burcin
Gonenli, Mehmet Gokhan https://orcid.org/0000-0003-2925-7048
Ural, Dilek https://orcid.org/0000-0003-0224-1433
Kim, Woonghee
Schwenk, Jochen M https://orcid.org/0000-0001-8141-8449
Zhang, Cheng https://orcid.org/0000-0002-3721-8586
Shoaie, Saeed
Nielsen, Jens https://orcid.org/0000-0002-9955-6003
Uhlén, Mathias
Borén, Jan https://orcid.org/0000-0003-0786-8091
Mardinoglu, Adil https://orcid.org/0000-0002-4254-6090
Funding for this research was provided by:
Knut and Alice Wallenberg Foundation (72110)
ScandiBio Therapeutics
Marie Sklodowska‐Curie PoLiMeR Innovative Training Network (812616)
Article History
Received: 19 May 2021
Revised: 16 September 2021
Accepted: 29 September 2021
First Online: 25 October 2021
Conflict of interest
: AM, JB, and MU are the founder and shareholders of ScandiBio Therapeutics and ScandiEdge Therapeutics. The other authors declare no conflict of interest.